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ABSTRACT
Objective: To study the influence of type of inhalation device on medication adherence of COPD
patients.
Methods: Adherence to inhalation medication of 795 patients was recorded from pharmacy
records over 3 years. It was expressed as percentage and deemed good at ≥75–≤125%, sub-
optimal ≥50–<75%, and poor <50% (underuse) or >125% (overuse). Since most patients used
more than one device, 1379 medication periods were analyzed.
Results: Patients using a Metered Dose Inhaler (MDI) or Diskus had a 2.3-fold and 2.2-fold
increased risk, respectively, of suboptimal adherence versus good adherence, compared to
Handihaler and a 2.1-fold and 2.2-fold increased risk, respectively, of underuse versus good
adherence compared to Handihaler. Turbuhaler, MDI, Respimat had a 7.9-fold, 3.5-fold, and 2.0-
fold increased risk, of overuse versus good adherence compared to Handihaler.
Conclusions: In COPD, adherence to inhalation medication is device-related. Overuse was most
pronounced for devices without a dose counter, devices with the ability to load a dosage without
actual inhalation, or devices lacking feedback of correct inhalation. The design of the device
seems to be related to underuse and overuse of inhaled medication. Future research might
investigate whether prescribing a different device with similar medication improves therapy
adherence.
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1. Introduction
In the treatment of Chronic Obstructive Pulmonary
Disease (COPD), therapy adherence is an important
issue. Therapy adherence to medication in COPD has
an extra dimension compared to, for example, the
treatment of cardiovascular disease, because most
medications are inhaled. In order to inhale medication
a patient has to use an inhalation device properly for an
effective drug delivery to the lung. The cognitive func-
tion, dexterity, and inhalation strength of a patient have
to be adequate to be able to use such an inhalation
device successfully.[1] Poor drug efficacy can be caused
by a decreased medication delivery associated with
incorrect inhaler technique for the device being used.
The design of the inhaler plays a significant role in
the effectiveness of inhaler therapy, with up to 94% of
the patients using their inhaler ineffectively.[2]
For example the effectiveness of a powdered drug to
inhale mainly depends on the inspiratory flow rate
generated by the patient and on the intrinsic resistance
of the DPI device. These two forces affect the dose
utilization, both the powder disaggregation and disper-
sion, its penetration into the airways, and finally the
efficacy of the treatment.[3]
The effectiveness of inhaled medications is also
strongly influenced by the patient’s medication adher-
ence, which has been shown to be associated with
reduced risk of death and hospitalizations due to
exacerbations in COPD.[4,5]
Medication adherence can be influenced by patient-
and medication-related factors. Patient-related factors
are disease and treatment acceptance, knowledge
about and faith in the treatment, effective patient–clin-
ician relationships, and routinization of drug therapy.[6–
8] Medication-related factors known to have a negative
influence on adherence are frequent daily use and
multiple dosing.[9] COPD patients often have a medica-
tion regimen that requires multiple daily dosages over a
prolonged period of time and they often use various
medications simultaneously. All these factors together
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can make therapy adherence for COPD patients a diffi-
cult task.
In COPD and asthma the level of patient satisfaction
with their inhaler device is observed to have a positive
influence on the treatment goals by improved compli-
ance.[10,11] In a study of Chrystyn et al. it was shown
that the principal inhaler attributes influencing overall
patient satisfaction were whether it was built to last and
would not break easily, whether it was easy to hold and
carry, and whether the instructions were simple and
easy to follow.[11] Feedback to indicate correct inhala-
tion is a feature patients also find important.[12] Rau
et al. stated, based on a summary of studies, the top
three features an ideal inhaler should possess including:
ease of use during an exacerbation, knowing how many
dosages are left, and overall ease of use.[13]
We therefore conducted a study to investigate the
relationship between therapy adherence and the
devices in which inhalation medication for COPD is
administered.
2. Methods
2.1. Setting and design
This study is part of the Cohort on Mortality and
Inflammation in COPD (COMIC), a single-center pro-
spective cohort study. From December 2005 to April
2010, 795 patients were included with a follow-up per-
iod of 3 years. Patients were recruited at the outpatient
clinic of the Department of Pulmonology, Medisch
Spectrum Twente Hospital, Enschede, located in the
Eastern part of The Netherlands, serving a catchment
population of approximately 264,000 persons. The
study was approved by the hospital’s Medical Ethical
Committee. All patients provided written informed con-
sent.[14,15]
To be eligible for the study patients had to have a
clinical diagnosis of COPD, as defined by the GOLD
criteria. Patients were consecutively enrolled when hos-
pitalized for an acute exacerbation of COPD or when
visiting the outpatient clinic in stable state. All surviving
patients completed the 3-year follow-up period and
were treated according to standard care. Demographic
data was collected from medical records. Lung function
and smoking status were both determined at baseline.
Lung function was measured by spirometry, performed
according to standardized guidelines.[16] Smoking sta-
tus was determined by the Vlagtwedde questionnaire.
[17] The primary outcome, therapy adherence, was
recorded from patients’ pharmacy records. The patients
were a priori not aware that their medication records
were going to be used for the monitoring of therapy
adherence. Theoretical duration of medication use was
calculated using information on dispensing date, total
supply, and dosage regimen. We computed the total
number of days for which patients had collected med-
ication during follow-up and divided this by the total
number of days between the first and last medication
collection during follow-up (36 months) plus the days
belonging to the last refill. The total follow-up could
therefore be prolonged with the days of the last refill.
[18] This was expressed as a percentage. Adherence
was deemed good if it was ≥75–≤125%, suboptimal
between ≥50–<75%, and poor below 50% (underuse)
or above 125% (overuse). In the literature there is no
consensus on acceptable therapy adherence, with defi-
nitions varying from >70% to >80% in clinical research
settings. We decided to set the limit for optimal adher-
ence at ≥75%, which is between these two definitions.
Next to this, we decided to choose an upper cutoff
point as well for good adherence (at 125%), in order
to exclude overuse from this category.[4,19–21] We
excluded medication when it was prescribed once
only or was used for less than 90 days. Seven devices
were considered in the study: Metered Dose Inhaler
(MDI), Autohaler, Respimat and the dry powder inhalers
Handihaler, Diskus, Cyclohaler, and Turbuhaler.
The devices used in this study were prescribed by
the physicians. With the current data we have no infor-
mation on whether each physician has taken the pre-
ference of the patient into account.
Therapy adherence with short-acting beta 2- and
muscarinic agonists, and formoterol were not analyzed
because these medications (unlike salmeterol) can be
used on demand as well and this confounds the calcu-
lation of adherence.[22] Because most patients in the
COMIC study were either on combined ICS preparations
or on single ICS preparations combined with either
long-acting anticholinergic or long-acting beta2-ago-
nists, as is recommended for the treatment of COPD,
many patients used more than one type of inhaled
medication. Since use of one medication in different
devices (e.g. MDI and Diskus) was scored separately
during the observation period, data on 1379 periods
of medication use are presented.
2.2. Statistical analyses
Baseline characteristics are reported as mean with SD for
continuous variables, or as numbers with corresponding
percentages for nominal variables. Not normally distrib-
uted continuous variables are reported as median with
the corresponding interquartile range (IQR).
We investigated the relationship between type of
device and therapy adherence with Nominal
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Regression analyses. Furthermore, potential confoun-
ders (age, sex, smoking status, lung function) were
first tested for their association with therapy adherence.
Variables associated with adherence were subsequently
tested for their association with type of device. For
categorical variables this association was tested by
means of Chi-square tests or Fisher exact tests, as
appropriate. For continuous variables this association
was tested with an ANOVA or Kruskall Wallis test as
appropriate. Variables that were both associated with
therapy adherence and type of device were all entered
in the multivariate Nominal Regression analyses.
Subsequently, potentially confounding variables with
the highest p-value were eliminated from the model
one by one until the fit of the model decreased sig-
nificantly, based on the −2 Log Likelihood.
Since not all inhaled drug substances COPD patients
use are available in every device, adherence to the type
of the device is in some instances identical to adher-
ence with the inhalation medication delivered by this
device. It is therefore not possible to study adherence
with an inhalation device without the interference of
the inhalation medication delivered by the device. Also,
because of the strong association between device and
medication a statistical correction for the inhaled med-
ication is not feasible because of the phenomenon of
multicolinearity.
To compare the four categories of therapy adher-
ence between inhalation devices we used multivariate
Nominal Regression analyses. Good adherence was set
as reference. Because the highest percentage of
patients with good adherence was observed for
Handihaler, this device was set as reference in Table 1.
We excluded Autohaler and Cyclohaler from these ana-
lyses because numbers were too small to obtain reliable
estimates. Furthermore, of the potential confounders
listed in Table 2, FEV1 in liters, FEV1 % predicted and
FEV1/VC ratio were all associated with type of device as
well as with therapy adherence and were therefore
potential confounders that should be entered to the
multivariate Nominal Regression analyses. Due to
multicolinearity between these three lung function
parameters, only the variable with the best model fit
was entered to multivariate Nominal Regression ana-
lyses, which was FEV1 in liters.
All statistical calculations were carried out with SPSS
version 21.0. P-values <0.05 were considered significant.
3. Results
The study population included 795 patients (Table 2).
Patients, mean age 68 years, were predominantly male
(61.1%). Almost three-quarter of the patients were ex-
smokers.
The devices most used were Handihaler (used for tio-
tropium) and MDI (used for salmeterol/fluticasone
(78.2%), fluticasone (6.2%), ciclesonide (5.4%), salmeterol
(4.2%), beclomethasone dipropionate extra fine (2.7%),
budesonide (2.0%), and beclomethasone (1.2%)). (Table 3)
We investigated therapy adherence for the different
types of inhalers. The results are listed in Table 4. The
percentages of patients with good therapy adherence
within the studied devices ranged from 38.5
(Cyclohaler) to 77.6% (Handihaler). Suboptimal adher-
ence ranged from 6.7 (Autohaler) to 38.5% (Cyclohaler),
Table 1. Nominal regression analyses of device versus therapy
adherence.
Odds Ratio 95% Conf. Interval
Suboptimal (n = 203) FEV1 (L) baseline 1.1 0.8–1.4
MDI 2.3 1.5–3.4
Diskus 2.2 1.4–3.4
Respimat 1.6 0.9–2.9
Turbuhaler 1.2 0.6–2.3
Underuse (n = 111) FEV1 (L) baseline 1.6 1.1–2.2
MDI 2.1 1.2–3.5
Diskus 2.2 1.2–3.7
Respimat 1.0 0.4–2.4
Turbuhaler 1.1 0.5–2.6
Overuse (n = 139) FEV1 (L) baseline 0.6 0.4–0.9
MDI 3.5 2.1–6.0
Diskus 1.7 0.9–3.3
Respimat 2.0 0.96–4.3
Turbuhaler 7.9 4.3–14.4
Optimal therapy adherence and Handihaler set as reference, corrected for
FEV1 in liters (L) at baseline.
Table 2. Baseline characteristics.
N = 795 Overall Good ≥75–≤125% Suboptimal ≤50–<75% Underuse <50% Overuse >125% P
Age in years (Mean (SD)) 67.8 (9.9) 66.5 (9.6) 66.5 (10.3) 64.3 (11.0) 67.2 (9.7) 0.100
Sex (Number of men (%)) 486 (61.1) 560 (61.6) 112 (53.6) 62 (53.9) 87 (59.6) 0.102
Smoking status (Number (%))
Current smoker 212 (26.7) 246 (27.1) 49 (23.4) 45 (39.1) 56 (38.4) 0.001
Ex-smoker 583 (73.3) 663 (72.9) 160 (76.6) 70 (60.9) 90 (61.6)
Lung function (Mean (SD))
FEV1 in liters 1.4 (0.6) 1.4 (0.6) 1.4 (0.5) 1.5 (0.6) 1.3 (0.5) 0.001
FEV1 % predicted 52.1 (19.4) 51.0 (17.8) 52.4 (18.4) 55.3 (20.1) 47.3 (16.9) 0.004
FEV1/VC ratio 44.5 (13.6) 42.3 (12.6) 45.5 (13.3) 48.0 (15.2) 42.3 (12.7) 0.000
Reproduced with permission from [14].
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while underuse ranged from 5.5 (Respimat) to 26.7%
(Autohaler) and overuse from 4.8 (Handihaler) to 26.8%
(Turbuhaler). The Chi-square test showed a significant
difference in therapy adherence between the studied
devices (p < 0.001).
For suboptimal therapy adherence the devices MDI
andDiskus differed significantly from theHandihaler com-
pared to optimal adherence. Patients using an MDI or a
Diskus had a 2.3 and a 2.2 times increased risk of sub-
optimal use versus optimal use compared to Handihaler.
Patients using an MDI had a 1.9 times increased risk of
suboptimal use versus optimal use compared to
Turbuhaler.
Also for underuse, MDI and Diskus differed signifi-
cantly from the Handihaler. With use of MDI or Diskus
the risk of underuse was 2.1 and 2.2 times higher
compared to the Handihaler and optimal use.
For overuse MDI and Turbuhaler differed significantly
from the Handihaler. MDI showed a 3.5 times higher
risk while the Turbuhaler showed a 7.9 times higher risk
of overuse compared to the Handihaler with optimal
therapy adherence.
Next to this MDI differed significantly from Diskus
with a 2.1 times increased risk of overuse compared to
Diskus with optimal adherence.
Turbuhaler showed a 3.9 times increased risk of over-
use compared to Respimat and a 2.2 times increased
risk of overuse compared to MDI and a 4.7 times
increased risk of overuse compared to Diskus with opti-
mal use.
FEV1 at baseline was related to poor adherence, both
underuse and overuse. Underuse was associated with a
higher FEV1 at baseline compared to good adherence,
while overuse was associated with a lower FEV1 at
baseline compared to good adherence.
4. Discussion
Therapy adherence to inhalation medication for the
treatment of COPD is related to the device in which
the medication is administered.
The highest percentage of optimal therapy adherence
was found for the Handihaler (78%). Overuse was found
most often for the MDI (14%) and Turbuhaler (27%).
Overuse can be due to both spillage and overdosing.
With the Turbuhaler spillage could be caused by the
design of the Turbuhaler, since it enables patients to
load the device several times by rotating the grip, with-
out actually inhaling. The ability of a device to indicate
the release of a dosage without actually inhaling there-
fore increases the risk of overuse as registered in phar-
macy records. Next to this, when a device does not
provide feedback on actually inhaling, a patient can
feel the need to load a dose and/or inhale again to be
sure about taking a dose, which results in overdosing.
For example the medication in the Turbuhaler has no
taste. This can make a patient insecure about whether
they have actually taken the medication. The majority
of the Turbuhaler records in our cohort contain bude-
sonide/formoterol (72%). In asthma maintenance ther-
apy this combination can be used on demand (SMART
regimen) when a patient experiences an increase in
symptoms due to the short onset of symptom relieve
of formoterol.[23] It is possible that this therapy advice
is used off-label for the treatment of COPD as well, and
because of the high prevalence of symptoms in
patients with COPD, this might lead to overuse.
For MDIs, overuse might in part be caused by for
example ‘test-puffs’ to see whether the device still con-
tains medication. Most MDIs lack a registration of
dosages left in the device. Maybe patients discard
Table 3. Prescribed inhalation medication per device.
Device Medication Number (%)
MDI Fluticasone 25 (6.2)
Salmeterol/Fluticasone 316 (78.2)
Salmeterol 17 (4.2)
Budesonide 8 (2.0)
Beclomethasone 5 (1.2)
Beclomethasone dipropionate extra fine 11 (2.7)
Ciclesonide 22 (5.4)
Diskus Fluticasone 48 (18.9)
Salmeterol/Fluticasone 184 (72.4)
Salmeterol 22 (8.7)
Respimat Tiotropium 128 (100)
Handihaler Tiotropium 438 (100)
Turbuhaler Budesonide 36 (28.3)
Formoterol/Budesonide 91 (71.7)
Cyclohaler Beclomethasone 13 (100)
Autohaler Beclomethasone dipropionate extra fine 15 (100)
Table 4. Number (%) of patients in the subgroups of therapy adherence per device.
Device Good ≥75–≤125% Suboptimal ≥50–<75% Underuse <50% Overuse >125% Months used median (IQR)
Handihaler (n = 438) 340 (77.6) 48 (11.0) 29 (6.6) 21 (4.8) 30.8 (17.5–36.1)
Respimat (n = 128) 89 (69.0) 20 (15.6) 7 (5.5) 12 (9.4) 20.1 (9.9–29.7)
Diskus (n = 254) 159 (62.6) 49 (19.3) 30 (11.8) 16 (6.3) 29.2 (14.2–35.4)
Turbuhaler (n = 127) 74 (58.3) 12 (9.4) 7 (5.5) 34 (26.8) 30.6 (17.9–36.5)
MDI (n = 404)* 235 (58.2) 74 (18.3) 38 (9.4) 57 (14.1) 25.1 (11.9–34.9)
Autohaler (n = 15) 7 (46.7) 1 (6.7) 4 (26.7) 3 (20.0) 15.3 (5.5–31.8)
Cyclohaler (n = 13) 5 (38.5) 5 (38.5) - 3 (23.1) 30.2 (11.0–37.6)
*MDI = Metered Dose Inhaler.
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their MDI too early because they do not know how
many dosages are left. This is in line with LaForce
et al. who showed that a dose counter relieves anxiety
about running out of medication.[24] In the COMIC
study population most MDI prescriptions were for the
salmeterol/fluticasone combination (78%). This MDI has
a counter to register the dosages left in the device. The
Respimat has a marker when a patient starts with the
last 10 dosages. The Turbuhaler has a marker that
becomes red when there are approximately 20 dosages
left, the least precise indicator of these three inhalers.
Despite the counters mentioned above we see overuse
happening.
The fact that MDIs are difficult to handle and require
critical hand–lung coordination, when not combined
with a spacer device, can be a cause of overuse. Many
studies have shown that numerous patients with MDIs
make critical inhalation errors that result in reduced
delivery of the medication into the lungs. When this is
experienced as reduced efficacy, patients might use
their inhaler again. The use of a spacer improves drug
availability.[25] It is possible that patients showed over-
use because they did not use a spacer and therefore
experienced reduced efficacy. Although it is common
practice in the studied population to prescribe an MDI
combined with a spacer including patient instruction,
the use of a spacer combined with an MDI could not be
derived from our database.
The dry powder inhalers, including Diskus, Handihaler,
and Turbuhaler, are flow-dependent devices and require
minimal coordination.[26] They are also associated with
lower rates of incorrect handling, when compared with
the MDI device (without spacer).[24]
Diskus and MDI have a higher risk of underuse com-
pared to Handihaler. With an MDI a patient can still
actuate the inhaler with little or no drug beyond the
maximum number of dosages left in the canister. The
pharmacy data show underuse while a patient may
believe he is still using his medication properly. This is
unlikely to happen with the Diskus once it is empty due
to the dose counter. In contrast to the MDI, the Respimat
cannot release a mist after the last dosage is delivered,
which prevents patients from using an empty device.
The literature shows that there are aspects in the
design of an inhaler that can influence a patient’s satis-
faction with an inhaler and therefore might influence
therapy adherence. A patient’s satisfaction with an
inhaler is likely to be based on the efficacy of the
inhaled medication as well.[10,11]
Previous analyses of the COMIC therapy adherence
data showed that therapy adherence to inhalation med-
ication for the treatment of COPD is related to the
medication prescribed. The medication dosed once
daily, tiotropium and ciclesonide, showed the highest
adherence. The good results for Handihaler might
therefore be influenced by the medication tiotropium.
Therapy adherence seems to be influenced by dosage
scheme and dosing once daily seems to improve ther-
apy adherence.[27] Also, corticosteroids are not bronch-
odilators and do not give immediate relief of
breathlessness, whereas tiotropium does relieve dys-
pnea, albeit with a relatively slow onset.[28] The med-
ication inhaled with a Diskus is dosed two times per day
and multiple dosing is known to decrease therapy
adherence. Salmeterol, inhaled with Diskus, also has a
slow onset of effect. To improve adherence numerous
combinations of drugs in one inhaler were introduced.
But the concept of improving adherence with the com-
bination of drugs in one inhaler could not be supported
with the COMIC data.[14]
Unfortunately, not all inhaled drug substances COPD
patients use are commercially available in every device,
so it is not possible to study adherence without the
interference of the inhalation medication delivered by
the device. However, as can be seen in Table 3, there
are several medications that are delivered in multiple
devices in which the design of a device can explain
aspects of therapy adherence.
Next to the type of device, also FEV1 at baseline was
related to poor adherence, both underuse and overuse.
Underuse was associated with a higher FEV1 at baseline
compared to good adherence, while overuse was asso-
ciated with a lower FEV1 at baseline compared to good
adherence. It is possible that patients with higher FEV1
show lower adherence levels because they feel less
need to use their medication. The opposite can be an
explanation for overuse in patients with a lower FEV1.
There are some potential limitations in our study.
Pharmacy records show maximum levels of medication
use in patients. There is no assurance the patient is
actually inhaling his medication successfully. Also
changes in dosage regimen advised by the prescriber
without giving a new prescription are not reflected in
the pharmacy data. It is plausible that the actual
inhaled drug volumes are lower than the volumes dis-
pensed through the pharmacy.[29,30]
Despite these limitations, this study has major
advantages. The therapy adherence data reflect real-
life use because of the observational design of the
study. Computerized pharmacy data made it feasible
to monitor medication adherence by tracking requests
for refills. Computerized drug-dispensing histories from
Dutch pharmacies are virtually complete and include
data concerning the dispensed drug, the prescriber, the
dispensing date, the amount dispensed, the prescribed
dose regimens, and the estimated duration of use. In
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the Netherlands, there is a strong pharmacy–patient
liaison for reimbursement of prescription drugs, a high
degree of computerization, the use of standardized
classification and coding systems, and a strong commit-
ment of pharmacists to surveillance of medication.
Next to this, the possibility to link adherence to lung
function, the reliable diagnosis of COPD (which studies
with pharmacy data alone often lack), and the 3-year
follow-up of medication use in COPD are of great benefit.
5. Conclusion
A striking result was the overuse with MDI and
Turbuhaler, which are devices that have the ability to
load a dosage without actual inhalation, or don’t have a
dose counter, or do not provide feedback of an inhala-
tion. Further research is needed to investigate whether
improving the design of an inhalation device (e.g.
devices without the ability to load a device without
actually inhaling, and devices providing a feedback on
correct inhalation) leads to improved adherence.
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